Search
N,N,N-trimethylglycinium
go.drugbank.com/drugs/DB04455InvestigationalBetaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341) … A naturally occurring compound that has been of interest for its role in osmoregulation.
Glutaral
go.drugbank.com/drugs/DB03266InvestigationalOne of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.
Categories: Compounds used in a research, industrial, or household settingINCB3284
go.drugbank.com/drugs/DB05130ExperimentalINCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawnXanthinol is a very potent water-soluble derivative of niacin that can be found in diet supplements. It is also known as xanthinol nicotinate. Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane a...
AT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.
Bopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker [pindolol].
Asundexian
go.drugbank.com/drugs/DB19088InvestigationalAsundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk
Bempegaldesleukin
go.drugbank.com/drugs/DB15140InvestigationalCabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)). … under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or